Asia Pacific Addictions Therapeutics Market is expected to reach US$ 1,781.09 Mn by 2027


PRESS RELEASE BY The Insight Partners 13 Dec 2020

Share this press on


Nicotine addiction treatment segment by type is estimated to lead the market growth during the forecast period

According to The Insight Partners market research study of “Asia Pacific Addictions Therapeutics Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Treatment Type, Drug Type, Treatment Centre, and Distribution Channel,” The Asia Pacific Addictions Therapeutics market is expected to reach US$ 1,781.09 million in 2027 from US$ 1,060.33 million in 2019. The market is estimated to grow with a CAGR of 6.8% from 2020 to 2027. The report highlights trends prevailing in the Asia Pacific Addictions Therapeutics market and the factors driving market along with those that act as hindrances.

Based on treatment type, the Asia Pacific addictions therapeutics market is segmented into nicotine addiction treatment, alcohol addiction treatment, opioid addiction treatment, and other substance addiction treatment. Drug addiction, also referred to as substance disorder, is a type of disease that hampers an individual’s brain, behavior, and metabolic processes leading to an inability to control. Nonmedical use and abuse of prescription drugs are becoming severe issues worldwide. Addiction to abusive substances is responsible for the death of millions of people across the world. According to the statistics of Movendi International, in 2017, the percentage of Chinese alcohol users was nearly doubled to 30%. The Addiction Center reports states that the number of people undertaking treatments for these addictions has increased in the recent years. Thus, the rising awareness among people about drug addiction treatment is likely to support the growth of the Asia Pacific addiction therapeutics market in the coming years. Similarly, awareness campaigns and government efforts to counteract drug abuse and promote medication for all sorts of addiction treatments would fuel the market growth during the forecast period.

The growth of the market is attributed to rising approval of new drugs and launch of digital therapeutics to treat addiction, conduction of various awareness campaigns and government efforts to counteract drug abuse and promote medication. However, high costs associated with drug development is hindering the growth of the addiction therapeutics market.

Indivior PLC, Pfizer Inc. and GlaxoSmithKline plc are among the leading companies operating in the Asia Pacific  addictions therapeutics market.

The report segments in Asia Pacific Addictions Therapeutics market as follows:

 By Treatment Type

  • Opioid Addiction Treatment
  • Alcohol Addiction Treatment
  • Nicotine Addiction Treatment
  • Other Substance Addiction Treatment

By Drug Type

  • Buprenorphine
  • Naltrexone
  • Bupropion
  • Disulfiram
  • Nicotine Replacement Products
  • Varenicline
  • Others

By Treatment Center

  • Inpatient Treatment Center
  • Residential Treatment Center
  • Outpatient Treatment Center

By Distribution Channel

  • Hospital Pharmacies
  • Medical stores
  • Others

By Country

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com

 

Download Free PDF Brochure